peach state health plan

Voretigene neparvovec-rzyl (Luxturna)

Prior Authorization Form/Prescription

Telephone: (800) 514-0083 option 2
Fax: (866) 374-1579

Date: _____ Date Medication Required: _____
Ship to: ❍ Physician ❍ Patient's Home ❍ Other _____

Patient Information

*Last Name:	*First Name:	Middle:	*DOB: ____ /____ /_____
Address:	City:	State:	Zip:
Daytime Phone:	Evening Phone:	*Sex: ☐ Male ☐ Female	

Insurance Information (*Attach copies of cards*)

*Primary Insurance:		Secondary Insurance:	
*ID #	Group #	ID #	Group #
City:	State:	City:	State:

Physician Information

*Name:	*Specialty:	NPI:	
Address:	City:	State:	Zip:
*Phone #:	Secure Fax #:	Office Contact:	

Administrating Facility

*Facility Name:

Primary Diagnosis

*ICD-10 Code: _____

☐Retinal dystrophy (Leber congenital amaurosis) ☐Other: _____

Prescription Information

MEDICATION	STRENGTH	*DIRECTIONS	QUANTITY	REFILLS
Luxturna (voretigene neparvovec-rzyl)				

Clinical Information

***** *Please submit supporting clinical documentation* *****

***THERAPY TYPE (choose one):** ☐INITIAL THERAPY ☐CONTINUATION OF THERAPY - Therapy start date: _____

1. Has patient had a positive response to the prescribed therapy? ☐Yes: _____ ☐No ☐Not applicable
2. Has patient previously been treated with Luxturna in the requested treatment eye(s)? ☐Yes ☐No
3. How many days have passed since treatment of first eye? _____ days

Complete this section ONLY if the patient is <u>initiating</u> therapy OR if the patient is <u>new</u> to this health plan:

4. Is therapy prescribed by or in consultation with an ophthalmologist? ☐Yes ☐No
5. Is diagnosis confirmed by presence of biallelic *RPE65* gene mutations? ☐Yes ☐No
6. Does patient have sufficient viable retinal cells evidenced by any of the following? ☐Yes ***Mark all that apply*** ☐No
   ☐Retinal thickness on spectral domain optical coherence tomography (i.e., areas of retina with thickness measurements > 100 microns within the posterior pole)
   ☐Fundus photography (i.e., presence of neural retina)
7. Does patient have significant vision loss evidenced by any of the following? ☐Yes ***Mark all that apply*** ☐No
   ☐Visual acuity of 20/60 or worse in both eyes ☐Visual field less than 20 degrees in any meridian
8. Has patient received intraocular surgery within the prior 6 months? ☐Yes ☐No
9. Please document patient's baseline full-field stimulus testing (FST) for blue and red light score: _____ log10(cd/m^2)

Complete this section ONLY for indications <u>other</u> than retinal dystrophy:

10. Has patient tried and failed, or is contraindicated to, accepted standards of care? ☐Yes ☐No
    If yes, submit documentation and answer the following:
    a. Please list all previous therapies:
    _____
    b. Was patient adherent to previously tried therapies? ☐Yes ☐No ☐No, patient intolerant to drug

Please continue to page 2.

peach state health plan

Telephone: (800) 514-0083 option 2
Fax: (866) 374-1579

Voretigene neparvovec-rzyl (Luxturna)

Prior Authorization Form/Prescription

Date: _____ Date Medication Required: _____
Ship to: ❍ Physician ❍ Patient's Home ❍ Other _____

Patient Name: _____ **DOB:** _____

Physician's Signature: _____ **Date:** _____ ☐DAW

INFORMATION BELOW IS TO BE COMPLETED BY THE HEALTH PLAN / CPS PA STAFF

Authorization Information

***Authorization number:**	***Decision Due Date:**
***J-Code:**	***Coverage:** ☐ State excludes ☐ COB (secondary)
***Line of Business:** ☐ Commercial ☐ Health Insurance Marketplace ☐ Medicaid ☐ Medicare	***Benefit:** ☐ Medical ☐ Pharmacy

***Criteria:**

☐ Centene Policy [**CP.PHAR.372 Voretigene Neparvovec-rzyl (Luxterna)**]
Date Policy last reviewed/approved by plan (we want to be sure we are using the version approved by your plan):
_____

☐ State of Health Plan specific (please include policy) _____

☐ Medicare Local Coverage Decision (LCD) specific for your region
Please include policy of link to LCD, followed by any applicable step therapy requirements. _____

☐ Medicare National Coverage Decision (NCD)
Please include policy of link to NCD, followed by any applicable step therapy requirements. _____